Anika Therapeutics Q1 2026: Solid Earnings & Pipeline Progress

Anika Therapeutics Q1 2026 earnings report is a standout, with total revenue surging 13% to $29.6M, driven by robust growth in commercial channels (12% to $12.6M) and OEM revenue (14% to $17M). Gross margins climbed to 64%, and adjusted EBITDA jumped over $4M YOY to $4.3M. Integrity, their flagship regenerative product, saw U.S. procedures soar 35% and revenue near $2M. Analysts praise the operational turnaround post-2025 divestitures, with strength in cost controls and pipeline momentum. The companys pipeline includes Hyalofasts FDA review, CINGALs EU MDR certification, and early promise in a new regenerative suture program. Guidance remains steady for full-year revenue between $114M and $122.5M, with commercial channels targeting 10-20% growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7b411bef9a112e51